News
Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...
As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...
Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma ...
Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed to reach the primary endpoint in a Phase II trial. Preliminary ...
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sanofi’s first-quarter sales and profit exceeded analyst expectations, but the company held tight on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback